Last week, a vaccine developed by China’s state-owned pharmaceutical giant Sinopharm was reported to have protected 86% of people against Covid-19 in trials conducted in the United Arab Emirates, winning approval for full public use in the Mideast country. The vaccine is based on using an inactivated version of the coronavirus to stimulate human immune systems.
China is of course not the only country developing a vaccine and scientists around the world have made unprecedented efforts to produce effective vaccines against SARS-COV-2, the virus behind the Covid-19 pandemic. Several major vaccine developers have reported promising results in recent weeks, leading to emergency government approvals for public use.
However significant obstacles still lie ahead of a global roll out. These include quickly ramping up enough production capacity to inoculate billions of people in the midst of a pandemic that has claimed more than 1.5 million lives in just a year. And in addition to the normal problems of transporting vaccines to the remotest corners of the world, some Covid-19 inoculations require special handling at super-cold temperatures.
Read the full story here.
Contact reporter Han Wei (email@example.com) and editor Marcus Ryder (firstname.lastname@example.org)